Remove Clinical Supply Remove Clinical Supply Chain Remove Manufacturing
article thumbnail

Untangling the Complexities of Cell and Gene Therapy Clinical Trials: A Supply Chain Perspective 

Pharmaceutical Technology

Nearly every biopharma with a portfolio of drugs in development spanning traditional small molecules and biologics and the newer CGT operates with separate clinical supply organizations per these therapy areas. This is due to major differences throughout the clinical supply chain in both requirements and management practices.

article thumbnail

Signant clinical supply chain software offers end-to-end visibility

Outsourcing Pharma

SmartSignals Supplies is designed to help trial teams get a handle on clinical trial supply chain management to avoid delays, waste, and cost overruns.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How to plan for uncertainty while maximizing the efficiency of your clinical sup…

The Pharma Data

Supply chain uncertainty is a challenge every clinical supply chain manager wrestles with – stemming from increasing product demand and quality, the growing complexity of clinical trial designs and a lack of visibility in the supply chain.

article thumbnail

How Concordance Healthcare Solutions Aims to Optimize the Supply Chain

XTalks

Many third-party supply chain solutions exist in the market, but none have the full suite offerings available in Surgence,” said Cody Fisher, Concordance EVP and strategic advisor in the company’s news release.

article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial.

article thumbnail

The Chemotherapy Drug Shortage: An Unprecedented Crisis

XTalks

Concerningly, the survey also revealed that only 40 percent of the surveyed NCCN cancer centers received any indication from manufacturers or suppliers about when carboplatin or cisplatin would be readily available again. These drugs are often generics and hence have a low unit price, making them less appealing to manufacturers.

Drugs 98
article thumbnail

Why demand is rising for secure and climate-controlled gene therapy services

Pharmaceutical Technology

As the clinical trials industry adapts to the rising demand, it must also tackle important challenges concerning the way advanced medicines like cell and gene therapies are handled. Cell and gene therapies are not your typical clinical supply chain.